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Limitation of podocyte proliferation improves renal function in
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Limitation of podocyte proliferation improves renal function in
experimental crescentic glomerulonephritis.
Background. Many forms of glomerular diseases are charac-
terized by injury to the glomerular visceral epithelial cell, or
podocyte, which usually results in depletion of podocyte num-
ber. However, in diseases where podocyte proliferation occurs
there is a rapid decline in renal function. The consequences of in-
hibiting podocyte proliferation on renal function have not been
fully established. At the level of the cell cycle, cyclin-dependent
kinase 2 (CDK2) is required for proliferation.
Methods. To determine if decreasing podocyte proliferation
improves renal function, CDK2 activity was reduced with the
purine analogue roscovitine in mice with antibody-induced ex-
perimental glomerulonephritis. Nephritic animals given vehicle,
dimethyl sulfoxide (DMSO), served as control. Blood urea ni-
trogen (BUN), proteinuria, and renal histology were assessed
at days 5 and 14 of disease.
Results. Inhibiting CDK2 activity resulted in a marked de-
crease in glomerular DNA synthesis [5-bromo-2′-deoxyridine
(BrdU) staining] in Roscovitine-treated animals at day 5 of
nephritis (P < 0.05 versus control). This was associated with
a significant decrease in BUN and glomerulosclerosis at day 14
(P < 0.01 versus control) and a decrease in the accumulation of
the extracellular matrix protein laminin (P < 0.01 versus con-
trol).
Conclusion. Inhibiting podocyte proliferation in experimen-
tal glomerulonephritis is associated with improvement in renal
function and histology, suggesting that inhibiting CDK2 activity
is a potential therapeutic target for glomerular diseases charac-
terized by podocyte proliferation.
The podocyte, or glomerular visceral epithelial cell, is
the target of both immune and nonimmune forms of in-
jury in many diverse glomerular diseases. The podocyte
may undergo several cellular responses to injury includ-
ing effacement, increased extracellular matrix (ECM)
synthesis, detachment, apoptosis, and, more unusually,
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reentry to the cell cycle with proliferation [1]. These
events may lead to a progressive decline in glomerular
filtration rate (GFR). The absence of a proliferative re-
sponse by podocytes to injury has been the focus of nu-
merous studies, as podocyte depletion may be central to
the development of progressive glomerulosclerosis, re-
gardless of the initiating pathology. Investigators have
shown that the progressive decline in podocyte number
following injury results in denudation of the underlying
glomerular basement membrane (GBM) in those areas
of podocyte loss, and that this underlies the development
of secondary focal glomerulosclerosis [2–9].
In contrast to their normal quiescent phenotype, recent
studies have documented that podocytes are capable of
proliferation in certain specific glomerular diseases, and
these include cellular focal segmental glomerulosclero-
sis (FSGS), collapsing glomerulopathy, and human im-
munodeficiency virus (HIV)-associated nephropathy [10,
11]. In these diseases, podocyte proliferation is associated
with collapse of the glomerular tuft and focal glomeru-
losclerosis, and the decline in renal function is typically ac-
celerated compared to those diseases that lack podocyte
proliferation [12, 13]. The formation of cellular crescents
within Bowman’s capsule occurs in a number of both hu-
man and experimental glomerulonephritides. The origin
of the cells comprising these crescents remains debated,
and likely varies with the initiating insult and stage of dis-
ease [14–16]. The involvement of proliferating, undiffer-
entiated podocytes has been demonstrated in mice with
experimental crescentic glomerulonephritis [17, 18], and
dysregulated proliferation of parietal epithelial cells is
also thought to contribute to crescent cellularity [16, 18].
However, the impact of inhibiting glomerular cell prolif-
eration, and hence crescent formation, on renal function
has not been fully established.
Cell proliferation is ultimately controlled by cell cycle
regulatory proteins. Proliferation requires that specific
cyclin-dependent kinases (CDK) are activated by partner
cyclins (reviewed in [19–21]). CDK2 is activated by cyclin
E in late G1 [22] and by cyclin A in S phase [23], when
active CDK2 is required for DNA synthesis. CDK activ-
ity is inhibited by endogenous negative cell cycle proteins
977
978 Griffin et al: Cell cycle and epithelial cell proliferation
called CDK inhibitors (reviewed in [24]). A number of
strategies have recently been developed to reduce CDK2
activity [25]. These include lowering the levels of CDK2
with antisense oligodeoxynucleotides [26], and the use
of specific purine analogues that inhibit CDK2 activity
without altering the protein levels of CDK2 [27–29]. Us-
ing a transgenic mouse model of HIV-associated collaps-
ing nephropathy, Gheradi et al [30] have recently shown
improvement in the histopathologic changes following
treatment with the CDK inhibitor, roscovitine.
The purpose of the current study was to (1) determine if
glomerular epithelial cell proliferation could be reduced
by inhibiting CDK2 activity, and (2) determine if this
reduction in proliferation altered renal function in exper-
imental glomerulonephritis. Our results show that reduc-
ing DNA synthesis with roscovitine was associated with
an improvement in renal function and a reduction in the
accumulation of ECM proteins, thus confirming the con-
tribution of dysregulated glomerular epithelial cell pro-
liferation and crescent formation to poor renal outcome
and demonstrating the benefit of its inhibition.
METHODS
Animal study and experimental design
The experimental protocol was reviewed and approved
by the Animal Care Committee of the University of
Washington, Seattle. Mice for this study were housed
in the animal care facility of the University of Washing-
ton under standardized specific pathogen-free conditions
(25◦C, 50% humidity, 12-hour light/dark cycle) with food
and water available ad libitum.
Experimental glomerulonephritis was induced in 8-
to 10-week-old male C57BL/6 mice by the intraperi-
toneal injection of a sheep antirabbit glomerular antibody
(0.5 mL/20 g body weight) on two consecutive days, as
previously detailed by our group [17, 31]. In this model,
DNA synthesis peaks at 5 days, returning to baseline at
14 days [31]. Briefly, rabbit glomeruli were isolated by
differential sieving and contained less than one tubular
fraction per 100 glomeruli. The sheep antirabbit glomeru-
lar antibody was produced in sheep immunized three to
four times at fortnightly intervals with lyophilized rab-
bit glomeruli emulsified in complete Freund’s adjuvant
at the first immunization and in incomplete Freund’s ad-
juvant subsequently. The antisera were heat inactivated
at 56◦C for 30 minutes, and IgG isolated using caprylic
acid [32]. Preliminary studies were performed to ensure
that dimethyl sulfoxide (DMSO), the vehicle for roscovi-
tine, did not alter the course of glomerular disease in this
model.
Nephritic animals were divided into two groups. The
first group (treatment) was given daily intraperitoneal
injections of the CDK2 inhibitor, roscovitine (gift of
Laurent Meijer) (2.8 mg/kg body weight) for 5 or 14 days.
The second group (control) was given daily injections
of the same volume of vehicle [20% (vol/vol) DMSO
in phosphate-buffered saline (PBS)]. The first injection
of roscovitine or DMSO was given 2 hours after the
second injection of the antiglomerular antibody to en-
sure that antibody binding was not altered (see below).
Roscovitine-treated and control animals were sacrificed
at day 5 (N = 6) and day 14 (N = 6).
To ensure that roscovitine reduced CDK2 activity,
a separate group of nephritic animals was given daily
roscovitine or DMSO and the animals were sacrificed on
day 4 (N = 3/group). Cortical protein was extracted as
previously reported, and CDK2 activity was measured by
a histone H1 kinase assay (see below).
All animals were injected with 5-bromo-2′-deoxyridine
(BrdU) (10 lL/g body weight) (Cell Proliferation Kit)
(Amersham Biosciences, Little Chalfont, Bucks, UK)
intraperitoneally 4 hours prior to sacrifice to measure
DNA synthesis (see below). Urine was collected from
each animal for 12 hours prior to sacrifice. Renal tissue
was snap frozen in liquid nitrogen and embedded in 22-
oxacalcitriol (OCT) compound (Miles, Elkart, IN, USA)
or fixed in either 10% neutral buffered formalin or methyl
Carnoy’s solution (60% methanol, 30% chloroform, and
10% acetic acid).
Laboratory data
Proteinuria was quantified by the sulfosalicylic acid
method. Serum blood urea nitrogen (BUN) was deter-
mined using a kit obtained from Sigma Chemical Co. (St.
Louis, MO, USA) (catalog number 535-B).
Histone H1 kinase assay
To determine the effect of roscovitine on CDK2 activ-
ity, a histone H1 kinase assay was performed at day 4 as
reported elsewhere [33]. The renal cortex from treated
and control animals was removed, sonicated and total
protein was extracted in TG buffer (1% Triton, 10%
glycerol, 20 mmol/L Hepes, and 100 mmol/L sodium
chloride with 10 lg/mL leupeptin, 10 lg/mL antipain,
10 lg/mL pepstatin, 0.1 mmol/L sodium orthovanadate,
and 50 mmol/L sodium fluoride) as reported elsewhere
[33]. In brief, 500 lg of protein lysate was immunoprecip-
itated with an antibody to CDK2 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and a histone H1 kinase
assay was performed. Positive controls consisted of cul-
tured mouse mesangial cells exposed to mitogenic growth
factors; negative controls consisted of preabsorbing the
antibody with immunizing peptide, and substituting the
primary antibody with an irrelevant antibody of the same
isotype.
Tissue preparation and histologic staining
Immunofluorescence staining was performed on snap-
frozen kidneys, sectioned at 4 lm and fixed in ice-cold
methanol for 20 minutes at −20◦C. Fixed tissues were
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processed and embedded in paraffin using routine proto-
cols. Tissues were sectioned at 4 lm thickness for staining
with periodic acid-Schiff (PAS) and immunohistochem-
istry and at 1 lm thickness for silver staining. All antibod-
ies were diluted in PBS with 1% bovine serum albumin
(BSA). Slides were viewed using a Leica confocal micro-
scope (Leica, Deerfield, IL, USA) using either bright-
field or appropriate epifluorescent optics.
Immunofluorescence staining. Frozen sections were
rehydrated in PBS and stained with fluorescein isoth-
iocyanate (FITC)-conjugated antibodies to sheep IgG
(Cappel, Durham, NC, USA), to ensure comparable
glomerular antibody deposition in the treated (roscov-
itine) and control (DMSO) mice. The autologous phase
of the disease was similarly assessed by immunostaining
with a FITC-conjugated antibody to mouse IgG (Cappel).
Staining was quantified on 50 consecutive glomeruli, and
graded 0 to 4+ based on the intensity of the staining
and the percentage of glomerular surface involved, as
described previously [17].
Light microscopy. Four micrometer methyl Carnoy’s-
fixed sections were stained with PAS reagent. Silver stain-
ing was also performed on formalin-fixed sections to
assess glomerular matrix accumulation. The percentage
of matrix proteins occupying the glomerular tuft was
quantitated and graded on a score of 0 to 4 as previously
described: grade 0, normal glomerulus; grade 1, sclerosis
involving less than 25%; grade 2, sclerosis involving 25%
to 50%; grade 3, sclerosis involving 50% to 75%; and
grade 4, sclerosis involving 75% to 100% of the glomeru-
lar tuft area [34]. A minimum of 50 glomeruli were eval-
uated in each biopsy, and results expressed as the mean
glomerular score ± standard deviation.
Indirect immunoperoxidase staining. For immunohis-
tochemistry, the fixed, paraffin-embedded sections were
deparaffinized with Histoclear (National Diagnostics,
Atlanta, GA, USA) and rehydrated in graded ethanol.
Antigen retrieval was performed on formalin-fixed tis-
sues by boiling tissues for 5 minutes in 10 mmol/L citric
acid, pH 6.0. Endogenous peroxidases were blocked with
3% hydrogen peroxide. Endogenous biotin was blocked
using an Avidin/Biotin Blocking Kit (Vector Laborato-
ries, Burlingame, CA, USA). Sections were incubated
overnight at 4◦C with the primary antibody. The sections
were washed repeatedly in PBS prior to incubation with
the appropriate biotinylated secondary antibody (Vector
Laboratories) for 1 hour at room temperature. The ABC-
Elite Reagent (Vector Laboratories) was used for signal
amplification and 3,3′-diaminobenzidine (DAB) (Sigma
Chemical Co.) with nickel enhancement was used as chro-
mogen. Slides were counterstained with PAS or methyl
green, dehydrated, and coverslipped.
To determine the effect of inhibiting CDK2 activity on
the number of glomerular cells undergoing DNA syn-
thesis, staining for BrdU incorporation was assessed on
formalin-fixed tissue (Cell Proliferation Kit) (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ, USA). Quanti-
tation was performed by counting the number of positive
staining nuclei in all cortical glomeruli, and expressed as
the number of positive cells/100 glomeruli.
To determine the presence of infiltrating cells in
the glomerulus, methyl Carnoy’s-fixed tissue sections
were stained with antibodies to neutrophils (clone 7/4)
(1:1000) (Caltag Laboratories, Burlingame, CA, USA)
or macrophages (F4/80 antigen) (1:1000) (Caltag Labo-
ratories), and methanol-fixed frozen tissue stained with
antibodies to T lymphocyte CD4 and CD8 antigens (both
1:1000) (Caltag Laboratories). Positive control tissues in-
cluded similarly fixed normal spleen and thymus.
Measurement of apoptosis was by the terminal deoxy
transferase (TdT) uridine triphosphate (UTP) nick-end
labeling (TUNEL) assay, performed as previously de-
scribed [35]. Briefly, formalin-fixed slides were deparaf-
finized and rehydrated followed by antigen retrieval as
above. Slides were incubated in proteinase K (Roche
Diagnostics Corp., Indianapolis, IN, USA), followed by
TdT (Amersham Pharmacia Biotech, Inc.) and bio-14-
deoxyadenosine triphosphate (dATP) (Invitrogen, Carls-
bad, CA, USA). Biotinylated ATP was detected using the
ABC reagent (Vector Laboratories), and slides counter-
stained with PAS.
Expression of the following podocyte specific proteins
were evaluated in methanol-fixed frozen tissue from nor-
mal and nephritic mice: nephrin (1:100) (Research Di-
agnostics, Inc., Flanders, NJ, USA), podocin (1:250) (gift
of Dr. Peter Mundel), Wilm’s tumor-1 (1:1000) (Santa
Cruz Biotechnology), glomerular epithelial protein 1
(GLEPP1) (1:50) (gift of Dr. Roger Wiggins), and podo-
calyxin (1:1000) (gift of Professor Marilyn Farquhar).
Double immunostaining for BrdU and podocalyxin
was performed on formalin-fixed tissue. BrdU immunos-
taining was detected as above using DAB as chromogen.
Following washing in PBS, the antipodocalyxin antibody
was applied and the slides incubated overnight at 4◦C.
Binding of this antibody was detected using a biotiny-
lated antirabbit IgG secondary (Vector Laboratories),
followed by streptavidin-conjugated Alexa Fluor 594
(Molecular Probes, Eugene, OR, USA).
The effect of inhibiting CDK2 activity on the ac-
cumulation of specific ECM proteins was assessed by
staining methyl Carnoy’s-fixed tissue for laminin (1:500)
(Chemicon International, Inc., Temecula, CA, USA) and
fibronectin (1:500) (Chemicon International, Inc.), and
quantified as above.
Negative controls consisted of substituting the primary
antibody with an irrelevant antibody of the same isotype.
Statistical analysis
All scores for immunohistochemical staining were ex-
pressed as mean ± standard deviation. Statistical signifi-
cance was evaluated using the Student t test.
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Fig. 1. Cyclin-dependent kinase 2 (CDK2) activity is reduced by
roscovitine in vivo. Histone H1 kinase assay in mice with crescentic
nephritis. CDK2 kinase activity was performed on 500 lg protein from
mouse kidney cortex. CDK2 activity was present in normal kidney cor-
tex (lane 1), increased substantially in nephritic mice (lane 2), and was
reduced to baseline by roscovitine (lane 3).
RESULTS
Roscovitine reduces CDK2 activity in experimental
glomerulonephritis
CDK2 activity was measured by the histone H1 kinase
assay. Figure 1 shows that CDK2 activity was increased
in control (DMSO) mice at day 4, which preceded the
peak of DNA synthesis in this model. Daily injections of
roscovitine significantly reduced, but did not completely
inhibit, CDK2 activity at day 4 in the treated group com-
pared to control animals.
Roscovitine does not interfere with antibody binding
Roscovitine and DMSO injections were started after
the administration of the antiglomerular antibody. Semi-
quantitation of the immunoflourescent staining for sheep
IgG, mouse IgG and C3 showed that antibody binding
was present in all glomeruli in the control and treated
animals at days 5 and 14, and there was no quantitative
difference in immunostaining in the treated and control
groups (results not shown). These results confirm that nei-
ther roscovitine nor DMSO interfered with the induction
of disease, and that the autologous phase of the immune
response was similar in both groups.
Renal function is improved with roscovitine
Renal function was assessed by measuring serum BUN
and proteinuria. There was a marked increase in BUN
levels in both control and roscovitine treated nephritic
animals at day 5 (normal 16.06 ± 3.46 mg/dL; control
67.9 ± 25.9 mg/dL; roscovitine treated 59.7 ± 14.5 mg/dL)
(P < 0.001 for both disease groups versus normal) (con-
trol versus roscovitine-treated NS), and the increase in
BUN persisted at day 14 in the disease control group
(52.6 ± 19.6 mg/dL) (Fig. 2). Inhibiting CDK2 activity
with roscovitine significantly reduced BUN at day 14
(17.4 ± 3.6) (P < 0.01 compared to control animals)
(Fig. 2).
The model used in the current study is not charac-
terized by marked proteinuria. Protein excretion was
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Fig. 2. Blood urea nitrogen (BUN) in normal mice and control and
roscovitine-treated nephritic mice. The increase in BUN is reduced by
treatment with roscovitine.
1.84 ± 0.38 mg/24 hours in normal mice, at day 5 2.57 ±
2.29 mg/24 hours in controls and 1.53 ± 0.82 mg/24 hours
in treated mice (both NS versus normal mice), and at
day 14 4.68 ± 3.12 mg/24 hours in control mice (NS ver-
sus normal mice) and 3.36 ± 1.29 mg/24 hours in treated
mice (P < 0.05 versus normal mice). There was no signif-
icant difference in proteinuria between the control and
roscovitine-treated nephritic animals at either time point.
Histologic severity of glomerulonephritis is reduced
by roscovitine
The formation of cellular glomerular crescents was re-
duced in mice treated with Roscovitine, and there was re-
duced accumulation of PAS-positive material within the
glomerulus (Fig. 3). The mean glomerulosclerosis score
at day 5 was 1.45 ± 0.25 in the control and 1.04 ± 0.09
in the roscovitine-treated nephritic mice (P < 0.05), and
sclerosis was also improved at day 14 (control 2.00 + 0.20;
roscovitine-treated 1.34 + 0.10) (P < 0.01) (Fig. 3E).
DNA synthesis by podocytes is decreased by reducing
CDK2 activity
To determine the impact of reducing CDK2 activity
on podocyte DNA synthesis, immunostaining was per-
formed for BrdU. An increase in BrdU-positive glomeru-
lar cells was seen at day 5, localized predominantly in
a podocyte distribution (Fig. 4). Lowering CDK2 activ-
ity with roscovitine significantly reduced the number of
glomerular cells staining positive for BrdU at day 5 (con-
trol 30.2 ± 13.1 positive cells/100 glomeruli; roscovitine-
treated 14.0 ± 7.1 positive cells/100 glomeruli) (P < 0.05).
BrdU immunostaining was similar in both control and
roscovitine-treated animals at day 14 (control 8.4 ± 5.4
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Fig. 3. Periodic acid-Schiff (PAS) staining in mice with anti-glomerular basement membrane (GBM) nephritis. (A) Crescent formation (arrows)
and accumulation of PAS-positive material within the glomerulus is seen at day 5 of control-treated mice. (B) Formation of cellular crescents (arrows)
and accumulation of extracellular material were reduced in mice treated with roscovitine. (C) Control mice show marked glomerulosclerosis at
day 14 of nephritis (arrows). (D) Glomerulosclerosis (arrows) is substantially ameliorated in roscovitine-treated mice. (E) Quantitation of matrix
accumulation scored on PAS-stained sections (see Methods section) [original magnification ×200 (A to D)].
positive cells/100 glomeruli; roscovitine-treated 8.5 ± 4.0
positive cells/100 glomeruli) (NS) (Fig. 4).
In this and similar models of glomerulonephritis, we
and others [16, 36] have observed a rapid, global de-
cline in immunostaining for the podocyte-specific pro-
teins nephrin, podocin, synaptopodin, Wilm’s tumor-1
and GLEPP1 (results not shown). In contrast, as previ-
ously reported [37], immunostaining for podocalyxin was
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Fig. 4. 5-bromo-2′-deoxyridine (BrdU) staining at day 5 is decreased by reducing cyclin-dependent kinase 2 (CDK2) activity. (A) Clusters of
BrdU-positive staining cells are seen within the crescents of control nephritic mice, indicated by arrows. (B) The number of BrdU-positive cells is
significantly reduced in roscovitine-treated mice. (C) Quantitation of BrdU staining [original magnification × 400 (A and B)].
relatively preserved (Fig. 5A and B), although not main-
tained in areas of established crescent formation. Double
immunostaining for BrdU and podocalyxin confirms that
in this model DNA synthesis does occur in podocytes
(Fig. 5C to E).
Occasional neutrophils were detected within the
glomeruli but in insufficient numbers to account for
the frequency of BrdU-positive staining. Immunostaining
for macrophages within the glomeruli was not detected;
however, periglomerular macrophages were observed,
outside Bowman’s capsule. Staining for T-lymphocyte
antigens was negative, but was detected in the positive
controls (results not shown). Taken together, these re-
sults show that the cells undergoing DNA synthesis were
resident glomerular cells.
To ensure that the change in DNA synthesis was not
due to differences in glomerular cell apoptosis, TUNEL
staining was performed at days 5 and 14. TUNEL staining
was not altered by lowering CDK2 activity with roscov-
itine at either day 5 (control 3.0 ± 1.1 positive cells/100
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Fig. 5. DNA synthesis is observed in podocytes at day 5 of anti-glomerular basement membrane (GBM) nephritis. Podocalyxin expression in normal
mice (A) is broadly maintained in nephritic mice (B). Double immunostaining for podocalyxin (C) and BrdU (color inverted image) (D) (arrows)
are superimposed (E), confirming that those cells within the glomerular tuft undergoing DNA synthesis are podocytes [original magnification ×200
(A and B), ×400 (C, D, and E)].
glomeruli; roscovitine-treated 5.3 ± 3.7 positive cells/100
glomeruli) or at day 14 (control 2.3 ± 1.5 positive cells/100
glomeruli; roscovitine-treated 1.7 ± 1.5 positive cells/100
glomeruli).
Specific ECM proteins are reduced by roscovitine
To determine the affect of lowering CDK2 activity on
specific ECM proteins shown to be important in diseases
of the podocyte, immunostaining was performed with an-
tibodies to laminin and fibronectin. Laminin staining was
sparse in normal glomeruli. However, laminin staining
increased at day 14 in control nephritic animals (mean
score 1.81 ± 0.22). Reducing CDK2 activity with roscovi-
tine significantly decreased the glomerular immunostain-
ing for laminin at day 14 (1.39 ± 0.33) (P < 0.01 versus
control) (Fig. 6). There was a trend for a parallel reduc-
tion in fibronectin staining at day 14, but this did not reach
significance (mean score control 1.37 ± 0.32; roscovitine-
treated 1.21 ± 0.43). These results show that reducing
podocyte proliferation by inhibiting CDK2 activity al-
ters the expression of specific ECM proteins following
glomerular injury.
DISCUSSION
In the current study we show that reducing CDK2 activ-
ity with roscovitine in an antibody-mediated model of ex-
perimental glomerulonephritis decreased podocyte DNA
synthesis, improved renal function, and reduced the accu-
mulation of specific ECM proteins. These data show for
the first time the potential therapeutic benefit of inhibi-
tion of podocyte proliferation in experimental crescentic
glomerulonephritis.
In order for cells to proliferate, CDK2 is activated
by partner cyclins during specific phases of the cell cy-
cle [19], although recent studies have challenged the ac-
cepted paradigm that cells are absolutely dependent on
CDK2 for cell cycle progression [38, 39]. The first aim
of this study was to determine if podocyte proliferation
could be reduced by decreasing CDK2 activity pharmaco-
logically in experimental glomerulonephritis. Indeed, our
results showed that reducing CDK2 activity with roscov-
itine significantly decreased podocyte DNA synthesis.
Inhibiting CDK2 activity with roscovitine has been suc-
cessfully used to decrease mesangial cell proliferation in
the Thy1 model of immune-mediated glomerulonephri-
tis [33], and to improve the collapsing glomerulopathy
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Fig. 6. Accumulation of extracellular matrix proteins is decreased by reducing cyclin-dependent kinase 2 (CDK2) activity. (A and B) Silver
stain showing increased matrix deposition in control mice at day 14 (A), which is reduced in roscovitine-treated mice (B). (C and D) Indirect
immunoperoxidase stain for laminin at day 14. The deposition of laminin seen in control mice (C) is reduced by treatment with roscovitine (D). (E)
Quantitation of laminin immunostaining at day 14 (see Methods section). There was a significant improvement in the laminin score in mice treated
with roscovitine. (F) Quantitation of fibronectin immunostaining at day 14. Although there was a trend for decreased accumulation of fibronectin
in roscovitine-treated mice, this did not reach significance compared to control mice [original magnification ×200 (A), ×400 (B)].
of HIV transgenic mice [30]. Interestingly, the dose of
roscovitine found to inhibit CDK2 activity in our study
was considerably lower (2.8 mg/kg daily) than that re-
quired to improve the histology of collapsing glomeru-
lopathy (120 mg/kg daily), suggesting inhibition of other
kinases may be important in the amelioration of that dis-
ease. Beyond nephrology, inhibiting CDK2 activity also
reduces smooth muscle cell proliferation following angio-
plasty [28] and prevents graft coronary arteriosclerosis
[26].
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The consequences of podocyte proliferation on the
accumulation of glomerular ECM proteins and on re-
nal function have not been well defined. Podocytes dif-
fer from glomerular mesangial and endothelial cells in
that they do not readily proliferate in response to ei-
ther immune or nonimmune forms of injury [40]. The
apparent lack of podocyte proliferation is central to
the development of secondary FSGS [2, 5, 7]. Yet, pro-
liferation of these specialized cells has recently been
shown in certain glomerular diseases, including collaps-
ing glomerulopathy, cellular FSGS, and HIV-associated
nephropathy [10, 11]. Interestingly, the rate of progres-
sion to end-stage renal failure is increased in glomeru-
lar diseases characterized by podocyte proliferation [12,
13]. The development of cellular crescents is observed
in both experimental and human glomerulonephritis, but
determining the origin of these cells has proved elusive.
The contribution of podocytes has previously been sus-
pected [16, 17], but confirmation has been difficult, as
in disease states the dysregulated podocyte loses expres-
sion of defining proteins. We have previously reported
the expression of the epithelial cell protein ezrin by the
crescentic cells in this model [17], with a proportion of
cells also expressing the platelet-derived growth factor
(PDGF) receptor b subunit, indicating parietal epithe-
lial cell origin. Similarly, expression of secreted protein
acidic and rich in cysteine (SPARC) by both visceral and
parietal epithelial cells precludes the use of this protein
to discriminate between the cell types contributing to the
crescent [41]. The potential of podocytes to proliferate
has been demonstrated in a mouse model of glomeru-
lonephritis [18], and the results may be applicable to
human crescentic nephritis. Moeller et al [18] generated
a mouse with constitutive expression of b-galactosidase
specifically in podocytes in vivo, then induced experi-
mental anti-GBM disease by injecting rabbit IgG in-
traperitoneally, followed 6 days later by an intravenous
injection of rabbit antimouse GBM antibody [18]. The
mice developed nephritis with crescent formation, con-
taining numerous b-galactosidase–expressing cells, con-
firming their podocyte origin. Furthermore, expression
of the nuclear proliferation marker Ki-67 by these cells
demonstrated the capability of these podocyte-derived
cells to undergo proliferation. In the current study, we ob-
served that immunostaining for podocalyxin is relatively
preserved compared to other podocyte-specific proteins,
possibly as a consequence of its long half life. Double im-
munostaining for BrdU and podocalyxin confirmed DNA
synthesis by podocytes in our experimental model.
The second major finding in this study was that reduc-
ing podocyte DNA synthesis by inhibiting CDK2 activity
was associated with a significant improvement in renal
function compared to control animals. Podocyte DNA
synthesis coincides with an early decrease in renal func-
tion in this model, and although decreasing DNA syn-
thesis with roscovitine reduced the increase in BUN, this
was not significant compared to control nephritic animals.
This may reflect additional compromise of podocyte func-
tion consequent to the acute effects of antibody binding.
However, at the later time point, renal function in the
roscovitine-treated animals was not significantly differ-
ent to normal mice, whereas that of control animals re-
mained markedly impaired. Our results also showed that
decreasing podocyte proliferation was associated with a
significant decrease in the accumulation of laminin, an
ECM protein which has been previously shown to be in-
creased following podocyte injury [42]. There was a trend
for the increase in fibronectin to be reduced in the treat-
ment group. The mechanism(s) underlying the role of
podocyte proliferation on the decline in GFR was not de-
termined in this study, and is likely multifactorial. These
include hemodynamic changes, loss of structural support
following capillary collapse, increased production of ox-
idants and proteinases, and an increased accumulation
of specific ECM proteins. Although the animal model
used in this study is not specific for crescentic glomeru-
lonephritis, the beneficial effects of inhibiting podocyte
proliferation suggest intervention with Roscovitine may
be indicated in comparable human diseases.
CONCLUSION
We show that lowering CDK2 activity with the purine
analogue roscovitine decreases podocyte proliferation in
immune-induced glomerulonephritis, and that this was
associated with a reduction in the accumulation of spe-
cific ECM proteins, and an improvement in renal func-
tion. Inhibiting CDK2 activity pharmacologically should
be considered an important target for the development of
future therapeutic strategies in glomerular diseases char-
acterized by podocyte proliferation.
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